New HIV vaccine combo enters first human safety trial

NCT ID NCT06905275

Terminated ⭐️ VACCINE ⭐️ Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tests two experimental HIV vaccines, UVAX-1107 and UVAX-1197, in 25 healthy adults without HIV. The goal is to check if the vaccines are safe and whether they trigger an immune response. Participants will receive injections and be followed for about a year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: UVAX-1107 and UVAX-1197 vaccines with 3M-052-AF + alum adjuvant
What this could lead to: If successful, this could point toward a safe and effective HIV vaccine that trains the immune system to fight the virus.
What could go wrong: This is a very early Phase 1 trial with only 25 people, so it is too soon to know if the vaccines will work. The study is also currently suspended, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV-1-INFECTION

Contacts and locations

Locations

Alabama CRS (#31788)

Birmingham, Alabama, 35222, United States
Columbia P&S CRS (#30329)

New York, New York, 10032, United States
University of Rochester Medical Center

Rochester, New York, 14642, United States
Vanderbilt Vaccine (VV) CRS (#30352)

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.